454 related articles for article (PubMed ID: 34418266)
61. In vivo therapeutic genome editing via CRISPR/Cas9 magnetoplexes for myocardial infarction.
Park H; Kim D; Cho B; Byun J; Kim YS; Ahn Y; Hur J; Oh YK; Kim J
Biomaterials; 2022 Feb; 281():121327. PubMed ID: 34952262
[TBL] [Abstract][Full Text] [Related]
62. Synthetic multi-layer nanoparticles for CRISPR-Cas9 genome editing.
Tang H; Zhao X; Jiang X
Adv Drug Deliv Rev; 2021 Jan; 168():55-78. PubMed ID: 32147450
[TBL] [Abstract][Full Text] [Related]
63. Artificial Virus Delivers CRISPR-Cas9 System for Genome Editing of Cells in Mice.
Li L; Song L; Liu X; Yang X; Li X; He T; Wang N; Yang S; Yu C; Yin T; Wen Y; He Z; Wei X; Su W; Wu Q; Yao S; Gong C; Wei Y
ACS Nano; 2017 Jan; 11(1):95-111. PubMed ID: 28114767
[TBL] [Abstract][Full Text] [Related]
64. Advances in therapeutic CRISPR/Cas9 genome editing.
Savić N; Schwank G
Transl Res; 2016 Feb; 168():15-21. PubMed ID: 26470680
[TBL] [Abstract][Full Text] [Related]
65. Outlook on the Security and Potential Improvements of CRISPR-Cas9.
Zha MJ; Cai CE; He PM
Mol Biotechnol; 2023 Nov; 65(11):1729-1736. PubMed ID: 36881252
[TBL] [Abstract][Full Text] [Related]
66. CRISPER/Cas in Plant Natural Product Research: Therapeutics as Anticancer and other Drug Candidates and Recent Patents.
Dey A; Nandy S
Recent Pat Anticancer Drug Discov; 2021; 16(4):460-468. PubMed ID: 34911411
[TBL] [Abstract][Full Text] [Related]
67. Integrating Combinatorial Lipid Nanoparticle and Chemically Modified Protein for Intracellular Delivery and Genome Editing.
Chang J; Chen X; Glass Z; Gao F; Mao L; Wang M; Xu Q
Acc Chem Res; 2019 Mar; 52(3):665-675. PubMed ID: 30586281
[TBL] [Abstract][Full Text] [Related]
68. Research Progress on Nanoparticles-Based CRISPR/Cas9 System for Targeted Therapy of Tumors.
Nie D; Guo T; Yue M; Li W; Zong X; Zhu Y; Huang J; Lin M
Biomolecules; 2022 Sep; 12(9):. PubMed ID: 36139078
[TBL] [Abstract][Full Text] [Related]
69. CRISPR/Cas9: an advanced tool for editing plant genomes.
Samanta MK; Dey A; Gayen S
Transgenic Res; 2016 Oct; 25(5):561-73. PubMed ID: 27012546
[TBL] [Abstract][Full Text] [Related]
70. CRISPR/Cas9 Genome Editing Tool: A Promising Tool for Therapeutic Applications on Respiratory Diseases.
Shaikh SB; Bhandary YP
Curr Gene Ther; 2020; 20(5):333-346. PubMed ID: 33045965
[TBL] [Abstract][Full Text] [Related]
71. The in vivo fate and targeting engineering of crossover vesicle-based gene delivery system.
Jiang XC; Zhang T; Gao JQ
Adv Drug Deliv Rev; 2022 Aug; 187():114324. PubMed ID: 35640803
[TBL] [Abstract][Full Text] [Related]
72. In vivo genome editing targeted towards the female reproductive system.
Sato M; Ohtsuka M; Nakamura S; Sakurai T; Watanabe S; Gurumurthy CB
Arch Pharm Res; 2018 Sep; 41(9):898-910. PubMed ID: 29974342
[TBL] [Abstract][Full Text] [Related]
73. Recent advances in CRISPR technologies for genome editing.
Song M; Koo T
Arch Pharm Res; 2021 Jun; 44(6):537-552. PubMed ID: 34164771
[TBL] [Abstract][Full Text] [Related]
74. [Exosome-mediated CRISPR/Cas9 system targets to cut the intercellular transmission function of hepatitis B virus genome].
Wang J; Chen R; Lu FM
Zhonghua Gan Zang Bing Za Zhi; 2019 Aug; 27(8):610-614. PubMed ID: 31594078
[No Abstract] [Full Text] [Related]
75. Application of CRISPR/Cas9 technology in sepsis research.
Wu M; Hu N; Du X; Wei J
Brief Funct Genomics; 2020 May; 19(3):229-234. PubMed ID: 32058568
[TBL] [Abstract][Full Text] [Related]
76. Applications of CRISPR-Cas9 Technology to Genome Editing in Glioblastoma Multiforme.
Al-Sammarraie N; Ray SK
Cells; 2021 Sep; 10(9):. PubMed ID: 34571991
[TBL] [Abstract][Full Text] [Related]
77. Ultra-efficient delivery of CRISPR/Cas9 using ionic liquid conjugated polymers for genome editing-based tumor therapy.
Huang Z; Yang T; Yu J; Gao Y; Weng Y; Huang Y; Li S
Biomater Sci; 2024 Mar; 12(7):1716-1725. PubMed ID: 38344762
[TBL] [Abstract][Full Text] [Related]
78. Challenges of in vitro genome editing with CRISPR/Cas9 and possible solutions: A review.
Ebrahimi V; Hashemi A
Gene; 2020 Aug; 753():144813. PubMed ID: 32470504
[TBL] [Abstract][Full Text] [Related]
79. Non-viral delivery of genome-editing nucleases for gene therapy.
Wang M; Glass ZA; Xu Q
Gene Ther; 2017 Mar; 24(3):144-150. PubMed ID: 27797355
[TBL] [Abstract][Full Text] [Related]
80. CRISPR-Cas9 technology and its application in haematological disorders.
Zhang H; McCarty N
Br J Haematol; 2016 Oct; 175(2):208-225. PubMed ID: 27619566
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
